Drugs / GenHevac-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00670839 | May 2008 → Dec 2011 | HIV infectious disease, hepatitis B virus infection | ANRS, Emerging Infectious Diseases | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genhevac-B | “1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6” NCT00670839 ↗ |
| Route | Intramuscular | “GenHevac-B 20 microgram intramuscular use at M0, M1 and M6” NCT00670839 ↗ |